- Correction
- Open access
- Published:
Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
Cancer Imaging volume 23, Article number: 46 (2023)
The Original Article was published on 27 December 2022
Correction to: Cancer Imaging 22 , 76 (2022).
During the publication process of the original article the arrows of Fig. 1 were misplaced. The correct figure is available in this correction article, the original article has been updated.
Example patient scanned over an extended period of time. Maximum Intensity Projection (MIP) SUV images (a, b), axial b900 DW images (c, d) and line graphs of tumor SUVmax and ADCmean quantification over time (e, f). Pre-therapy (t0) and early post-therapy (t1) images are shown in inverted grey scale. A large decrease in MTV between the pre-therapy (MTV = 337 ml) and early post-therapy (MTV = 19 ml) scans was measured, as visualized by the MIP SUV images (a, b). Although this patient had a large total tumor burden pre-therapy, the OS was long (48.2 months with last follow-up as end-point). SUVmax and ADCmean tumor quantification over time (e, f), indicate an intra-tumor heterogenic response to the CAR T-cell therapy. Target lesion selection post-therapy is shown for SUVmax (red arrows) and ADCmean (blue arrows). These tumors are also highlighted in the corresponding color in the line graphs (e, f)
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s40644-022-00513-y.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Sjöholm, T., Korenyushkin, A., Gammelgård, G. et al. Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy. Cancer Imaging 23, 46 (2023). https://doi.org/10.1186/s40644-023-00548-9
Published:
DOI: https://doi.org/10.1186/s40644-023-00548-9